GlobeNewswire·Nov 6, 2026, 4:30 PM ET

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ORIC Pharmaceuticals granted 14,800 non-qualified stock options & 2,400 restricted stock units to a new non-executive employee on November 2, 2026.
The employee began their tenure in October 2026, & the grants were issued under the 2022 Inducement Equity Incentive Plan as material inducement per Nasdaq Rule 5635(c)(4).
Stock option exercise prices equal the closing price of ORIC's common stock on the grant date, with 25% vesting after one year & the remainder vesting monthly over the following 36 months.
One-third of the restricted stock units will vest on each of the first three anniversaries of the grant date, contingent on continued employment.
ORIC is a clinical-stage oncology company developing rinzimetostat for prostate cancer & enozertinib for NSCLC, with offices in South San Francisco & San Diego.